Company / Operating Income per Share
Jazz Pharmaceuticals Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$7.10
FY2025
5-year range
-$7.10 / $11.51
FY2021-FY2025
Trend
-161.6%
vs FY2024
Sector context
#186 of 201
Health Care
What the data says
Among 201 Health Care companies, Jazz Pharmaceuticals is in the bottom 7% for operating income per share. Operating Income per Share has fluctuated over the past 10 years, ranging from $-7.10 in FY2025 to $11.51 in FY2024.
Based on SEC 10-K filings.
-7.10 in FY2025.
Declined from $9.15 to $-7.10 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 201This company -$7.10 Sector average -$3.23
▼
-119.5% below sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 161.6% year-over-year.
- Ranks #186 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$7.10 | -161.6% |
| FY2024 | $11.51 | +25.8% |
| FY2023 | $9.15 | +49.2% |
| FY2022 | $6.13 | -35.3% |
| FY2021 | $9.48 | -13.5% |
| FY2020 | $10.95 | +19.5% |
| FY2019 | $9.16 | -8.8% |
| FY2018 | $10.05 | +13.6% |
| FY2017 | $8.84 | +177.1% |
| FY2016 | $3.19 | -61.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026